107 related articles for article (PubMed ID: 597414)
1. [Depression of the immune response to lymphoma allotransplant with the use of 5-(3,3-dimethyl-1-triazeno)-imidazol-4-carboxamide (DTIC)].
Giampietri A; Puccetti P; Circolo A; Menconi E
Boll Soc Ital Biol Sper; 1977 Jun; 53(11):922-6. PubMed ID: 597414
[No Abstract] [Full Text] [Related]
2. In vitro lymphocyte stimulation and the generation of cytotoxic lymphocytes with drug-induced antigenic lymphomas.
Testorelli C; Franco P; Goldin A; Nicolin A
Cancer Res; 1978 Mar; 38(3):830-4. PubMed ID: 75062
[TBL] [Abstract][Full Text] [Related]
3. The immunodepressive and hematotoxic activity of imidazole-4-carboxamide,5-(3,3-dimethyl-1-triazeno) in mice.
Vecchi A; Fioretti MC; Mantovani A; Barzi A; Spreafico F
Transplantation; 1976 Dec; 22(6):619-24. PubMed ID: 795112
[TBL] [Abstract][Full Text] [Related]
4. Long-term depression of two primary immune responses induced by a single dose of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC).
Puccetti P; Giampietri A; Fioretti MC
Experientia; 1978 Jun; 34(6):799-800. PubMed ID: 658308
[TBL] [Abstract][Full Text] [Related]
5. Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide and its metabolites on Novikoff hepatoma cells.
Beal DD; Skibba JL; Whitnable KK; Bryan GT
Cancer Res; 1976 Aug; 36(8):2827-31. PubMed ID: 179708
[TBL] [Abstract][Full Text] [Related]
6. In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide.
Contessa AR; Bonmassar A; Giampietri A; Circolo A; Goldin A; Fioretti MC
Cancer Res; 1981 Jun; 41(6):2476-82. PubMed ID: 7016315
[TBL] [Abstract][Full Text] [Related]
7. Cell kinetics and immunoegenicity of lymphoma cells treated with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DIC) in vivo.
Silvestrini R; Testorelli C; Goldin A; Nicolin A
Int J Cancer; 1977 May; 19(5):664-9. PubMed ID: 863544
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of normal or drug-treated lymphoma cells in lethally irradiated mice.
Riccardi C; Fioretti MC; Giampietri A; Puccetti P; Goldin A; Bonmassar E
J Natl Cancer Inst; 1978 May; 60(5):1083-90. PubMed ID: 642028
[No Abstract] [Full Text] [Related]
9. Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea, and L-phenylalanine mustard on B16, Cloudman S91, and Harding-Passey mouse melanomas.
Hill HZ; Hill GJ; Miller CL; Pfaller M; Weiss K; Galin M
Cancer Res; 1979 Mar; 39(3):934-9. PubMed ID: 427782
[TBL] [Abstract][Full Text] [Related]
10. Attempt to alter antigenic structure of normal tissues by treatment with dimethyl-triazeno-imidazole-carboxamide in vivo.
Nicolin A; Fagnani R; Nicolotti G; Goldin A
Experientia; 1976 Jun; 32(6):741-2. PubMed ID: 780128
[TBL] [Abstract][Full Text] [Related]
11. Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo.
Riccardi C; Fioretti MC; Giampietri A; Puccetti P; Goldin A
Transplantation; 1978 Feb; 25(2):63-8. PubMed ID: 146282
[TBL] [Abstract][Full Text] [Related]
12. Increased immunogenicity of murine lymphoma cells following exposure to gamma rays in vivo.
Guadagni F; Roselli M; Fuggetta MP; Perno CF; Goldin A; Giuliani A
Chemioterapia; 1984 Dec; 3(6):358-64. PubMed ID: 6529777
[TBL] [Abstract][Full Text] [Related]
13. Antimetastatic action and hematological toxicity of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma.
Sava G; Giraldi T; Lassiani L; Nisi C
Cancer Res; 1984 Jan; 44(1):64-8. PubMed ID: 6690062
[TBL] [Abstract][Full Text] [Related]
14. Transplantation resistance of drug-treated hybrid or allogeneic mice against murine lymphomas. I. Immunopharmacology studies.
Bonmassar A; Riccardi C; Rivosecchi-Merletti P; Goldin A; Bonmassar E
Int J Cancer; 1980 Dec; 26(6):819-29. PubMed ID: 6971268
[TBL] [Abstract][Full Text] [Related]
15. Immunosensitivity and histocompatibility antigens in drug-altered leukemic cells.
Nicolin A; Franco P; Testorelli C; Goldin A
Cancer Res; 1976 Jan; 36(1):222-7. PubMed ID: 1248001
[TBL] [Abstract][Full Text] [Related]
16. [Dimethyl-triazeno-imidazol-carboxamide (DTIC)--a new cytostatic agent].
Klepp O
Tidsskr Nor Laegeforen; 1975 Sep; 95(27):1550-1. PubMed ID: 1179374
[No Abstract] [Full Text] [Related]
17. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
[TBL] [Abstract][Full Text] [Related]
18. Effects of 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide [NSC 45388, DTIC] on neuroblastoma cells in culture.
Culver B; Sahu SK; Vernadakis A; Prasad KN
Biochem Biophys Res Commun; 1977 Jun; 76(3):778-83. PubMed ID: 20080
[No Abstract] [Full Text] [Related]
19. Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide.
Bonmassar E; Bonmassar A; Vadlamudi S; Goldin A
Cancer Res; 1972 Jul; 32(7):1446-50. PubMed ID: 4402275
[No Abstract] [Full Text] [Related]
20. Transplantation resistance of drug-treated allogeneic mice against murine lymphomas--II. Studies with various tumor-host combinations.
Bonmassar A; Rivosecchi-Merletti P; Barzi A; Goldin A; Bonmassar E
Int J Immunopharmacol; 1981; 3(4):391-9. PubMed ID: 7333720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
